查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598714

2 型糖尿病藥物市場：按藥物、應用和分佈分類 - 全球預測 2025-2030

Type 2 Diabetes Drugs Market by Drug (Injectables, Oral), Application (Cardiovascular Safety, Glycemic Control, Hypoglycemia Avoidance), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年2型糖尿病藥物市值為711.7億美元，預計到2024年將達到770.7億美元，複合年成長率為8.81%，到2030年將達到1285.5億美元。

2 型糖尿病藥物市場包括透過調節血糖值來控制和治療 2 型糖尿病的藥物。這些藥物包括不同類型的藥物，如Metformin、磺醯尿素類、噻唑烷類、DPP-4抑制劑、GLP-1受體促效劑和SGLT2抑制劑。 2 型糖尿病盛行率不斷上升、人口老化以及糖尿病管理意識不斷增強，推動了該市場的發展。預防心血管疾病、神經病變和視力障礙等併發症的需求強調了對這些藥物的需求。儘管主要用於門診環境，但人們對個人化醫療和遠端醫療選擇也越來越感興趣。最終用途範圍集中在醫院、診所和居家醫療。關鍵的成長要素包括給藥系統的創新、醫療保健支出的增加和保險覆蓋範圍的擴大。特別值得注意的是，使用人工智慧和機器學習來客製化治療計劃的機會不斷增加。公司可以透過與高科技公司建立夥伴關係來利用這一點。然而，挑戰仍然存在，例如嚴格的監管要求和副作用，這些都阻礙了採用。學名藥降低了利潤率，也阻礙了市場成長。創新領域包括口服胰島素製劑、長效注射劑和針對BETA細胞功能障礙的藥物。基因療法和基於微生物的治療是開拓的研究途徑，可能會重新定義糖尿病管理。整體而言，市場競爭激烈，需要大量研發投資來維持創新。能夠透過新穎的治療方法滿足未滿足的需求，同時確保負擔能力和易用性的公司可能會在這個動態環境中佔據優勢。透過利用資料分析獲得患者洞察並整合數位健康工具，您可以進一步鞏固您的市場地位。

主要市場統計
基準年[2023] 711.7億美元
預測年份 [2024] 770.7億美元
預測年份 [2030] 1285.5億美元
複合年成長率（%） 8.81%

市場動態：快速發展的 2 型糖尿病藥物市場的關鍵市場洞察

2 型糖尿病藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球糖尿病盛行率的重要性
    • 由於不健康的飲食和久坐的生活方式，肥胖人口不斷增加
    • 政府提高健康意識的措施和計劃
  • 市場限制因素
    • 影響品牌聲譽的產品召回
  • 市場機會
    • 製藥商在糖尿病治療方面的進展
    • 增加研發和醫療基礎建設的投資
  • 市場挑戰
    • 嚴格的法規環境和漫長的核准流程

波特五力：駕馭第 2 型糖尿病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對第 2 型糖尿病藥物市場的影響

外部宏觀環境因素在塑造第 2 型糖尿病治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解第二型糖尿病治療藥物市場的競爭狀況

對第 2 型糖尿病治療藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 2 型糖尿病藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估第 2 型糖尿病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃 2 型糖尿病藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 2 型糖尿病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界性糖尿病盛行率的重要性
      • 由於不健康的飲食和久坐的生活方式，肥胖人數不斷增加
      • 政府提高健康意識的措施和計劃
    • 抑制因素
      • 產品回憶影響品牌聲譽
    • 機會
      • 製藥商在糖尿病治療方面的進展
      • 增加研發和醫療基礎建設的投資
    • 任務
      • 嚴格的法規環境和漫長的核准流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 2 型糖尿病藥物市場（依藥物）

  • 注射
    • Aspart
    • Exenatide
    • 甘精胰島素
    • 胰島素
    • 來拉魯肽
    • 普拉姆林潮汐
  • 口服
    • α葡萄Glucosidase抑制劑
    • 雙胍
    • Dipeptidyl Peptidase-4抑制劑
    • 類升糖素
    • 促效劑
    • 分泌促效劑
    • 鈉葡萄糖共同輸送體2抑制劑
    • 磺醯尿素類
    • 胰島素增敏劑

第7章 2 型糖尿病藥物市場：依應用分類

  • 心血管安全
  • 血糖控制
  • 避免低血糖

第8章 2型糖尿病藥物市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美及南美第二型糖尿病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太第二型糖尿病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲第2型糖尿病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group
Product Code: MRR-7162E4C3E9C3

The Type 2 Diabetes Drugs Market was valued at USD 71.17 billion in 2023, expected to reach USD 77.07 billion in 2024, and is projected to grow at a CAGR of 8.81%, to USD 128.55 billion by 2030.

The Type 2 Diabetes Drugs market encompasses medications that are designed to manage and treat type 2 diabetes by regulating blood sugar levels. These drugs include a variety of treatment types such as metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is driven by the growing prevalence of type 2 diabetes, aging populations, and increased awareness of diabetes management. The necessity of these drugs is underscored by the need to prevent complications like cardiovascular disease, neuropathy, and vision problems. Application primarily involves outpatient settings, though there is rising interest in personalized medicine and telehealth options for delivery. End-use scope focuses on hospitals, clinics, and homecare settings. Key growth factors include innovations in drug delivery systems, rising healthcare expenditure, and expanded insurance coverage, which enhance product accessibility. Notably, there's a burgeoning opportunity in the use of artificial intelligence and machine learning to tailor treatment plans. Companies can leverage partnerships with tech firms to capitalize on this. However, challenges remain, such as stringent regulatory requirements and side effect profiles of these drugs, which can deter adoption. Market growth is also hampered by generic drugs, which curtail profit margins. Innovation areas include the development of oral insulin, longer-duration injectables, and drugs targeting beta-cell dysfunction. Gene therapy and microbiome-based therapies represent untapped research avenues that might redefine diabetes management. Overall, the nature of the market is highly competitive with significant R&D investment required to sustain innovation. Companies that can address unmet needs with novel therapeutic agents while ensuring affordability and ease-of-use will likely excel in this dynamic environment. Utilizing data analytics for patient insights and integrating digital health tools can further strengthen market positions.

KEY MARKET STATISTICS
Base Year [2023] USD 71.17 billion
Estimated Year [2024] USD 77.07 billion
Forecast Year [2030] USD 128.55 billion
CAGR (%) 8.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significance of diabetic prevalence globally
    • Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
    • Government initiatives and programs to create health awareness
  • Market Restraints
    • Products recall affecting brand reputation
  • Market Opportunities
    • Advancements in diabetic medications by pharmaceutical manufacturers
    • Rising investment in R&D and healthcare infrastructure development
  • Market Challenges
    • Stringent regulatory environment and time-consuming approval process

Porter's Five Forces: A Strategic Tool for Navigating the Type 2 Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Type 2 Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Type 2 Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Type 2 Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Type 2 Diabetes Drugs Market

A detailed market share analysis in the Type 2 Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Type 2 Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Type 2 Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Type 2 Diabetes Drugs Market

A strategic analysis of the Type 2 Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 2 Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Peptron, Pfizer Inc., and Sanofi Group.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.
  • Based on Application, market is studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significance of diabetic prevalence globally
      • 5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.3. Government initiatives and programs to create health awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Products recall affecting brand reputation
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
      • 5.1.3.2. Rising investment in R&D and healthcare infrastructure development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and time-consuming approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Type 2 Diabetes Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Injectables
    • 6.2.1. Aspart
    • 6.2.2. Exenatide
    • 6.2.3. Glargine
    • 6.2.4. Insulin
    • 6.2.5. Leraglutide
    • 6.2.6. Pramlintide
  • 6.3. Oral
    • 6.3.1. Alpha-Glucosidase Inhibitors
    • 6.3.2. Biguanides
    • 6.3.3. Dipeptidyl Peptidase-4 Inhibitors
    • 6.3.4. Glucagon-Like Peptide
    • 6.3.5. Receptor Agonists
    • 6.3.6. Secretagogues
    • 6.3.7. Sodium Glucose Cotransport 2 Inhibitors
    • 6.3.8. Sulfonylureas
    • 6.3.9. Thiazolidinediones

7. Type 2 Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Safety
  • 7.3. Glycemic Control
  • 7.4. Hypoglycemia Avoidance

8. Type 2 Diabetes Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Type 2 Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Type 2 Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Bayer Inc
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Chugai Pharmaceutical Co., Ltd.
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. Eli Lilly and Company
  • 10. GSK plc
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Peptron
  • 15. Pfizer Inc.
  • 16. Sanofi Group

LIST OF FIGURES

  • FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. TYPE 2 DIABETES DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TYPE 2 DIABETES DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 245. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023